Articles From: Mercedes-Benz to Equip Car Models With Plug-In Hybrids - Report to Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA


2014/9/13
Daimler AG's (DAI.XE) Mercedes-Benz unit plans to equip 10 car models with plug-in hybrid engines by 2017, Mercedes management board member for development, Thomas Weber, tells weekly magazine Automobilwoche.
Sign-up for Mercedes-Benz to Equip Car Models With Plug-In Hybrids - Report investment picks
2014/9/15
Mercer has added three Talent executives to its business leadership team, underscoring the firm’s commitment to delivering winning solutions for its clients.
Sign-up for Mercer Adds Seasoned Talent Leaders to Drive Client Impact investment picks
NEW YORK, July 17, 2014 (GLOBE NEWSWIRE) -- Mercer International (Nasdaq:MERC) (TSX:MRI.U) will release its second quarter financial results for the period ended June 30, 2014 on Thursday, July 31, 2014, after the close of the market.
Sign-up for Mercer International Inc. Announces Conference Call for Second Quarter 2014 Results investment picks
NEW YORK, July 31, 2014 (GLOBE NEWSWIRE) -- Mercer International Inc. (Nasdaq:MERC) (TSX:MRI.U) today reported results for the second quarter ended June 30, 2014.
Sign-up for Mercer International Inc. Reports 2014 Second Quarter Results investment picks
Mercer announced today that it has entered into a definitive agreement to acquire a 34% stake in South Africa-based Alexander Forbes Group Holdings Limited (Alexander Forbes), becoming a key strategic shareholder in the upcoming listing of Alexander Forbes on the Johannesburg Stock Exchange (JSE). Alexander Forbes also announced today its intention to list on the JSE.
Sign-up for Mercer to Acquire 34% Strategic Stake in South Africa-Based Alexander Forbes investment picks
http://media.marketwire.com/attachments/201210/52876_mblogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1132037&ProfileId=051205&sourceType=1 SOUTH BURLINGTON, VT --
Sign-up for Merchants Bancshares, Inc. Announces Dividend Declaration and Earnings Release Calendar investment picks
SOUTH BURLINGTON, Vt., July 22, 2014 /PRNewswire/ -- Merchants Bancshares, Inc. (NASDAQ: MBVT) , the parent company of Merchants Bank, today announced net income of $3.41 million and $6.82 million , or diluted earnings per share of $0.54 and $1.07 for the three and six months ended June 30, 2014 , respectively.
Sign-up for Merchants Bancshares, Inc. Announces Second Quarter 2014 Results investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND ® (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.
Sign-up for Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis.
Sign-up for Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the company’s common stock for the fourth quarter of 2014.
Sign-up for Merck Announces Fourth-Quarter 2014 Dividend investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2014.
Sign-up for Merck Announces Second-Quarter 2014 Financial Results investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix.
Sign-up for Merck Begins Tender Offer to Acquire Idenix investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) at a purchase price of $24.50 per share.
Sign-up for Merck Completes Tender Offer to Acquire Idenix investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent.
Sign-up for Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the future appointment of Michael J.
Sign-up for Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015 investment picks
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today issued its 2013 global corporate responsibility report.
Sign-up for Merck Publishes 2013 Global Corporate Responsibility Report investment picks
WHITEHOUSE STATION, N.J. , Sept.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
NEW YORK (MarketWatch) -- Shares of Merck (MRK) rose 1.1% in premarket trade after the drug giant reported second-quarter profit of $2 billion, or 68 cents a share, up from $906 million, or 30 cents a share, in the same period a year ago.
Sign-up for Merck shares rise in premarket trade as profit, sales beat forecasts investment picks
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices’ (ACIP’s) updated pneumococcal vaccine recommendations for adults 65 years of age and older.
Sign-up for Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults investment picks
2014/9/12
By Monica Houston-Waesch German pharmaceutical group Merck KGaA (MRK.XE) said Friday it will discontinue the clinical development program of its Tecemotide drug to treat lung cancer.
Sign-up for Merck to End Clinical Development of Lung Cancer Drug Tecemotide investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 29.
Sign-up for Merck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29 investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.
Sign-up for Merck to Participate at the Morgan Stanley Global Healthcare Conference investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 – 30.
Sign-up for Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014 investment picks
"Speaking Up" is Vital, Given the Significant Impact of the Disease on Women WHITEHOUSE STATION, N.J. , July 17, 2014 /PRNewswire/ -- Merck (NYSE: MRK) , known as MSD outside the United States and Canada , today announced that Maria Davis – a music industry promoter and HIV advocate – and Positive Women's Network – USA (PWN- USA ) – are joining its national HIV education campaign, I Design.
Sign-up for Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma.
Sign-up for Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status.
Sign-up for Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Mercedes-Benz to Equip Car Models With Plug-In Hybrids - Report to Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices